Riverbridge Partners LLC Sells 35,540 Shares of Charles River Laboratories International, Inc. $CRL

Riverbridge Partners LLC trimmed its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 35.8% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 63,788 shares of the medical research company’s stock after selling 35,540 shares during the period. Riverbridge Partners LLC owned approximately 0.13% of Charles River Laboratories International worth $11,003,000 at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of the business. Tema Etfs LLC bought a new position in shares of Charles River Laboratories International during the fourth quarter valued at $26,000. Los Angeles Capital Management LLC bought a new stake in Charles River Laboratories International in the 4th quarter worth about $42,000. Sfam LLC purchased a new position in Charles River Laboratories International in the 4th quarter worth about $43,000. Activest Wealth Management lifted its stake in Charles River Laboratories International by 10,900.0% during the 4th quarter. Activest Wealth Management now owns 220 shares of the medical research company’s stock valued at $44,000 after acquiring an additional 218 shares during the period. Finally, Elyxium Wealth LLC bought a new position in Charles River Laboratories International during the 4th quarter valued at about $46,000. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently commented on the stock. Weiss Ratings lowered shares of Charles River Laboratories International from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, June 16th. Robert W. Baird set a $213.00 price objective on shares of Charles River Laboratories International in a research report on Friday, May 8th. UBS Group raised their target price on shares of Charles River Laboratories International from $170.00 to $175.00 and gave the stock a “neutral” rating in a report on Wednesday, February 25th. JPMorgan Chase & Co. cut their target price on shares of Charles River Laboratories International from $165.00 to $160.00 and set a “neutral” rating for the company in a research report on Monday, April 13th. Finally, CLSA upgraded shares of Charles River Laboratories International from a “hold” rating to an “outperform” rating and boosted their target price for the company from $167.00 to $219.00 in a research note on Friday, May 29th. Twelve research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $211.00.

Charles River Laboratories International Price Performance

NYSE CRL opened at $186.08 on Wednesday. The company has a quick ratio of 1.03, a current ratio of 1.36 and a debt-to-equity ratio of 0.90. The firm has a market capitalization of $8.96 billion, a P/E ratio of -49.49, a PEG ratio of 2.07 and a beta of 1.46. The company has a 50-day moving average price of $175.14 and a 200-day moving average price of $182.81. Charles River Laboratories International, Inc. has a 52 week low of $144.26 and a 52 week high of $228.88.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Thursday, May 7th. The medical research company reported $2.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.96 by $0.10. Charles River Laboratories International had a negative net margin of 4.59% and a positive return on equity of 15.36%. The company had revenue of $995.83 million during the quarter, compared to analyst estimates of $977.46 million. During the same period in the previous year, the business posted $2.34 earnings per share. The firm’s quarterly revenue was up 1.2% compared to the same quarter last year. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. Equities research analysts anticipate that Charles River Laboratories International, Inc. will post 11.05 earnings per share for the current year.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.